Contact Information: Contact: Rachel Levine Director Corporate Development & Communications Cleveland BioLabs, Inc. T: (646) 284-9439 E: rlevine@cbiolabs.com
Cleveland BioLabs Publishes New Insights Into Mechanism of Action of Curaxins, Extending Their Clinical Potential
| Source: Cleveland BioLabs, Inc.
BUFFALO, NY--(Marketwire - November 18, 2009) - Cleveland BioLabs, Inc. (NASDAQ : CBLI ) today
announced that a breakthrough discovery into the mechanism of action of the
Company's first generation Curaxin anticancer compounds was published in an
international health science journal, Cell Cycle (Neznanov et al., Cell
Cycle 8:23, 1-11; December 1, 2009).
The published study examined the ability of the Company's prototype Curaxin
(CBLC102, or quinacrine) to inhibit heat shock response, a major adaptive
pro-survival pathway that rescues cells from stressful conditions involving
accumulation of misfolded proteins (known as proteotoxic stress). Tumor
cells typically become dependent on constitutive activity of this salvaging
mechanism making them selectively susceptible to its inhibitors, especially
if applied in combination with certain cancer therapies provoking
proteotoxic stress.
Cleveland BioLabs Chief Scientific Officer and co-corresponding author,
Andrei Gudkov, Ph.D., D. Sci., commented, "We are very excited by the
prospective development path defined by the published results. The
potential use of Curaxins as adjuvants to cancer therapies inducing
proteotoxic stress, such as bortezomib (Velcade®) or thermotherapy, opens
a whole new avenue of potential treatment options that may broaden the
spectrum of responding tumors by cutting off an escape mechanism. We are
strongly encouraged by these results and believe that they further support
the potential of our lead next generation Curaxin compound, CBLC137."
An accompanying commentary published by leaders in this field of research,
the Signal Transduction and Molecular Pharmacology Team of the Cancer
Research UK Centre for Cancer Therapeutics at The Institute of Cancer
Research, Haddow Laboratories (de Billy et al., Cell Cycle 8:23, 1-3;
December 1, 2009), noted, "Inhibition of the HSF1 stress pathway has many
potential advantages for the treatment of cancer and can be seen as part of
a general strategy to target the critical stress pathway dependence of
malignant cells, as well as other crucial cancer cell dependencies and
addictions."
The Cell Cycle publication may be found online at:
http://www.landesbioscience.com/journals/cc/article/10179/
About Cleveland BioLabs, Inc.
Cleveland BioLabs, Inc. is a drug discovery and development company
leveraging its proprietary discoveries around programmed cell death to
develop treatments for cancer and protection of normal tissues from
exposure to radiation and other stresses. The Company has strategic
partnerships with the Cleveland Clinic, Roswell Park Cancer Institute,
ChemBridge Corporation and the Armed Forces Radiobiology Research
Institute. To learn more about Cleveland BioLabs, Inc., please visit the
company's website at http://www.cbiolabs.com.
This press release contains forward-looking statements within the meaning
of the Private Securities Litigation Reform Act of 1995. Forward-looking
statements reflect management's current expectations, as of the date of
this press release, and involve certain risks and uncertainties. The
Company's actual results could differ materially from those anticipated in
these forward-looking statements as a result of various factors. Some of
the factors that could cause future results to materially differ from the
recent results or those projected in forward-looking statements include the
"Risk Factors" described in the Company's Annual Report on Form 10-K filed
with the Securities and Exchange Commission on March 30, 2009.